NICE received an appeal against the Final Evaluation Determination on the above HST evaluation from the following organisations:
• Aegerion Pharmaceuticals
• Lipodystrophy UK
The company which markets this technology (Aegerion Pharmaceuticals) has requested reconsideration of this topic in line with the HST Interim Methods and Process guide, to undertake further work to address the concerns outlined by the committee. Consequently, the Final Evaluation Document for this evaluation is being withdrawn. Therefore an appeal hearing will not be held.
A further update will be provided in due course